Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers

Trial Profile

Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Afatinib (Primary) ; Capecitabine
  • Indications Biliary cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Jan 2017 Trial design presented at the 2017 Gastrointestinal Cancers Symposium
    • 17 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top